General
Preferred name
lixisenatide
Synonyms
Lixisenatide acetate ()
Lyxumia ()
Lixisenatide (acetate) ()
P&D ID
PD008982
CAS
1997361-87-1
320367-13-3
Tags
available
drug
Approved by
PMDA
EMA
FDA
First approval
2013
Drug indication
Type-2 diabetes
Drug Status
approved
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Lixisenatide is a GLP-1 peptide mimetic. The sequence for this drug differs from native GLP-1 as depicted in , and is largely based on the sequence of exendin-4 from the Gila monster (Heloderma suspectum). Lixisenatide is licensed as a once-daily mealtime GLP-1 receptor agonist administered by sub-cuteneous injection. (GtoPdb)
Compound Sets
9
AdooQ Bioactive Compound Library
A14076
Cayman Chemical Bioactives
39739
DrugCentral
4815
DrugCentral Approved Drugs
4815
DrugMAP
DM0QJDC
DrugMAP Approved Drugs
DM0QJDC
Guide to Pharmacology
7387
Natural product-based probes and drugs
TargetMol Bioactive Compound Library
TP1469
External IDs
9
Properties
(calculated by RDKit )
Molecular Weight
4855.54
Hydrogen Bond Acceptors
71
Hydrogen Bond Donors
70
Rotatable Bonds
169
Ring Count
8
Aromatic Ring Count
5
cLogP
-22.91
TPSA
2060.16
Fraction CSP3
0.65
Chiral centers
42.0
Largest ring
6.0
QED
0.01
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
GPCR/G protein
Target
GLP-1
Biosynthetic Origin
Peptide (Ribosomal)
Therapeutic Indication
Antidiabetic
Therapeutic Class
Metabolic Disorders
Source data